Zymeworks

ZYME · Nasdaq · United States

Share price · ZYME

$26.04-0.03 (-0.12%) 3M

close as of 2026-11-18 · 24h delayed · vol 1.1M (0.8x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when ZYME's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 12 Nov 2026-8.9%
  2. 11 Nov 2026-7.6%
  3. 26 Aug 2026+6.7%
  4. 25 Aug 2026-4.5%
  5. 21 Aug 2026+7.9%
  6. 13 Aug 2026+3.3%
  7. 30 Jun 2026+8.5%
  8. 8 May 2026-10.2%
  9. 12 Mar 2026-7.6%

    Nothing announced by ZYME that day or the session before.

  10. 10 Mar 2026+5.0%

Share of unusual movement by asset

For each asset, the share of ZYME's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Zanidatamab
events and moves
2326%
Revefenacin (Yupelri)
events and moves
1shown from 8 days
Assets with fewer than 8 event days, together—0%
Other company news (earnings, financing, releases naming no asset)—13%
Sessions with no dated event—61%

Assets

(2 total)
2Total Assets
2Approved
0Phase 3 / Filed
0Phase 1–2 / Early
5Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Revefenacin(Yupelri)
Approved
Muscarinic receptors (antagonist)Small molecule
Chronic Obstructive Pulmonary Disease
Approved
HER2Multispecific antibody
Non-Small Cell Lung CancerBiliary Tract CancerBreast CancerGastric Cancer
HER2-Positive Breast Cancer

Discontinued programmes (1)

Development of these assets stopped. Each page states the sourced discontinuation and keeps the trials as evidence history.

Upcoming events

(4 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
ZanidatamabPhase 2Breast Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Cancer, Colorectal Cancer, Endometrial Cancer …
Est. primary completion 2026-12-31 · NCT06695845 · CT.gov ↗
What to watch
2027 (1)
December 2027 (1)
ZanidatamabPhase 2HER2-positive Breast Cancer, Breast Cancer
Est. primary completion 2027-12-29 · NCT07102381 · CT.gov ↗
What to watch
2028 (2)
April 2028 (1)
ZanidatamabPhase 3Metastatic HER2-positive Breast Cancer
Est. primary completion 2028-04-28 · NCT06435429 · CT.gov ↗
What to watch
December 2028 (1)
ZanidatamabPhase 3Biliary Tract Cancer
Est. primary completion 2028-12-01 · NCT06282575 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(9)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

31 August 2026Topline resultZanidatamabPhase 3 HERIZON-GEA-01 second interim analysis: ZIIHERA plus chemotherapy improved overall survival versus trastuzumab plus chemotherapy
25 August 2026ApprovalZanidatamabFDA approves Ziihera regimens in first-line HER2+ gastroesophageal adenocarcinoma
US, FDA · Source ↗
25 August 2026FDA action dateZanidatamabPDUFA target date August 25, 2026
US, FDA · Source ↗
August 2026ApprovalZanidatamabFDA updates Boxed Warning on Zanidatamab (BLA761416)
US, FDA · FDA · Source ↗
27 April 2026Filing acceptedZanidatamabFDA accepts Ziihera sBLA for first-line HER2+ GEA
US, FDA · Source ↗
27 April 2026Priority reviewZanidatamabFDA grants Priority Review to Ziihera sBLA
US, FDA · Source ↗
3 March 2026Topline resultAmpreloxetine (TD-9855)CYPRESS (NCT05696717) Phase 3 did not meet its primary endpoint; programme wound down
Theravance Biopharma, Inc. · Source ↗
1 July 2025ApprovalZanidatamabEC conditional marketing authorization for Ziihera in HER2-positive BTC
EU, EC · Source ↗
30 May 2025ApprovalZanidatamabNMPA conditionally approves zanidatamab in China for HER2+ BTC
CN, NMPA · Source ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$256M$36M$100M+ $0 short-term inv.—-$24M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$4.6M$27M$179M+ $91M short-term inv.$45M-$32M operating cash flowreport ↗
2026-Q1$2.4M$34M$244M+ $120M short-term inv.$44M-$46M operating cash flowreport ↗
2025-Q3$28M$36M$65M+ $187M short-term inv.$20M-$31M operating cash flowreport ↗
2025-Q2$49M$34M$98M+ $183M short-term inv.—$12M operating cash flowreport ↗
2025-Q1$27M$36M$76M+ $189M short-term inv.$23M-$3.4M operating cash flowreport ↗
2024-Q3$16M$36M$122M+ $175M short-term inv.$30M-$5.9M operating cash flowreport ↗
2024-Q2$19M$29M$71M+ $259M short-term inv.$38M-$25M operating cash flowreport ↗
2024-Q1$10M$32M$115M+ $230M short-term inv.$32M-$38M operating cash flowreport ↗
2023-Q3$17M$33M$94M+ $201M short-term inv.$29M-$43M operating cash flowreport ↗
2023-Q2$7.0M$39M$142M+ $198M short-term inv.$51M-$6.4M operating cash flowreport ↗
2023-Q1$36M—$182M+ $159M short-term inv.$24M-$83M operating cash flowreport ↗
2022-Q3$2.6M—$96M+ $70M short-term inv.$48M-$73M operating cash flowreport ↗
2022-Q2$5.4M—$199M$65M-$55M operating cash flowreport ↗
2022-Q1$1.9M—$276M$73M-$55M operating cash flowreport ↗
2021-Q3$4.4M—$253M$61Mreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$106M$137M$41M+ $188M short-term inv.$20M-$33M operating cash flowreport ↗

Zymeworks reported revenue of $105.97M for fiscal 2025, up 38.9% YoY from $76.3M, and R&D spend of $137M, up 1.8% YoY from $134.62M. Cash and equivalents were $41.16M, with a net loss of $81.13M (quarterly net burn of $81.13M).

The company guided to approximately $300.0M in aggregate adjusted gross operating expenditures (non-GAAP) over 2026–2028, with 2026 adjusted gross operating expenses expected about 20% lower than 2025’s $170.5M. Pipeline and partnered highlights include ongoing Phase 1 studies for ZW191 and ZW251, IND submissions for ZW209 and ZW1528 in 2026, Jazz’s planned completion of the Ziihera sBLA in first-line HER2+ gastroesophageal adenocarcinoma in 1Q 2026 with potential launch in 2H 2026, pasritamig data presented at ASCO-GU by Johnson & Johnson, and a $250.0M royalty-backed note financing from Royalty Pharma alongside $62.5M utilized for share repurchases under the $125.0M buyback program.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$76M$135M$66M+ $160M short-term inv.$31M-$110M operating cash flowreport ↗
2023-FY$76M$144M$158M+ $217M short-term inv.$30M-$118M operating cash flowreport ↗
2022-FY$412M$209M$401M+ $91M short-term inv.—$144M operating cash flowreport ↗
2021-FY$27M—$202M+ $51M short-term inv.$53M-$192M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 15 sales ($6.4M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-18Platshon Scott · EVP, Chief Business OfficerOption exercise37,037——Form 4
2026-11-18Platshon Scott · EVP, Chief Business OfficerOpen-market sale15,292$24.95$382KForm 4
2026-11-18Platshon Scott · EVP, Chief Business OfficerOption exercise (derivative)37,037——Form 4
2026-11-13Moore Paul Andrew · Chief Scientific OfficerOption exercise25,000$5.82$146KForm 4
2026-11-13Moore Paul Andrew · Chief Scientific OfficerOpen-market sale7,367$26.14$193KForm 4
2026-11-13Moore Paul Andrew · Chief Scientific OfficerOpen-market sale7,374$26.09$192KForm 4
2026-11-13Moore Paul Andrew · Chief Scientific OfficerOpen-market sale25,000$26.04$651KForm 4
2026-11-13Moore Paul Andrew · Chief Scientific OfficerOption exercise (derivative)25,000——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 211 reporting institutions held 70.3M shares ($1.8B, 101.8% of shares outstanding).

#InstitutionSharesValue
1EcoR1 Capital, LLC22,970,388$575.2M
2Rubric Capital Management LP7,000,000$175.3M
3BlackRock, Inc.4,553,888$114.0M
4BVF INC/IL3,734,142$93.5M
5PERCEPTIVE ADVISORS LLC3,510,078$87.9M
6MORGAN STANLEY2,480,568$62.1M
7BNP PARIBAS ASSET MANAGEMENT Holding S.A.1,908,039$47.8M
8VANGUARD CAPITAL MANAGEMENT LLC1,705,580$42.7M
9CITADEL ADVISORS LLC1,150,018$28.8M
10DIMENSIONAL FUND ADVISORS LP1,139,135$28.5M
11Nextech Invest, Ltd.1,113,946$27.9M
12STATE STREET CORP1,011,777$25.3M
13Capricorn Fund Managers Ltd1,007,210$25.2M
14DEUTSCHE BANK AG\921,250$23.1M
15ARROWSTREET CAPITAL, LIMITED PARTNERSHIP743,898$18.6M